ResearcherQueensland University of TechnologyActive in the last 2 years
Amir Avan
Matched on ORCID iD 0000-0001-9561-2306; OpenAlex author ID A5101889687. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 0, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 18
2022: 2 papers · 2023: 1 paper · 2024: 2 papers · 2025: 1 paper
Papers 6
- Recent advances of circulating biomarkers with potential diagnostic, prognostic, and therapeutic value in pancreatic cancer: Limitations of clinical applicatio… Last author DOI 10.1016/j.prp.2025.156045↗
- The circadian clock as a potential biomarker and therapeutic target in pancreatic cancer. Last author DOI 10.1007/s11010-023-04790-4↗
- Exploring Splicing Modulation as an Innovative Approach to Combat Pancreatic Cancer: SF3B1 Emerges as a Prognostic Indicator and Therapeutic Target. Co-author DOI 10.7150/ijbs.92671↗
- Therapeutic Potential of Targeting Transforming Growth Factor-beta (TGF-β) and Programmed Death-ligand 1 (PD-L1) in Pancreatic Cancer. Co-author DOI 10.2174/0113894501264450231129042256↗
- Angiotensin-converting Enzyme Inhibitors and Angiotensin Receptor Blockers as Potential Therapeutic Options for Pancreatic Cancer. Co-author DOI 10.2174/1568009622666220517104411↗
- Association of a Genetic Variant in the Cyclin-Dependent Kinase Inhibitor 2B with Risk of Pancreatic Cancer. Co-author DOI 10.52547/rbmb.11.2.336↗
Closest collaborators
The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Majid Khazaei · 5 shared papers, 2022–2025 · strength 0.91
- Paper Recent advances of circulating biomarkers with potential diagnostic, prognostic, and therapeutic value in pancreatic ca… DOI 10.1016/j.prp.2025.156045↗
- Paper The circadian clock as a potential biomarker and therapeutic target in pancreatic cancer. DOI 10.1007/s11010-023-04790-4↗
- Paper Therapeutic Potential of Targeting Transforming Growth Factor-beta (TGF-β) and Programmed Death-ligand 1 (PD-L1) in Pan… DOI 10.2174/0113894501264450231129042256↗
- Gordon A. Ferns · 3 shared papers, 2022–2023 · strength 0.49
- Paper Therapeutic Potential of Targeting Transforming Growth Factor-beta (TGF-β) and Programmed Death-ligand 1 (PD-L1) in Pan… DOI 10.2174/0113894501264450231129042256↗
- Paper Angiotensin-converting Enzyme Inhibitors and Angiotensin Receptor Blockers as Potential Therapeutic Options for Pancrea… DOI 10.2174/1568009622666220517104411↗
- Paper Association of a Genetic Variant in the Cyclin-Dependent Kinase Inhibitor 2B with Risk of Pancreatic Cancer. DOI 10.52547/rbmb.11.2.336↗
- Ghazaleh Pourali · 2 shared papers, 2023–2024 · strength 0.37
- Zahra Yousefli · 1 shared paper, 2025 · strength 0.23
- Btissame El Hassouni · 1 shared paper, 2024 · strength 0.18
- Daniela Carbone · 1 shared paper, 2024 · strength 0.18
- Annalisa Comandatore · 1 shared paper, 2024 · strength 0.18
- Giulia Mantini · 1 shared paper, 2024 · strength 0.18
- I Gede Putu Supadmanaba · 1 shared paper, 2024 · strength 0.18
- Rocco Sciarrillo · 1 shared paper, 2024 · strength 0.18
- Luca Morelli · 1 shared paper, 2024 · strength 0.18
- Godefridus J. Peters · 1 shared paper, 2024 · strength 0.18
- Elisa Giovannetti · 1 shared paper, 2024 · strength 0.18
- Patrizia Diana · 1 shared paper, 2024 · strength 0.18
- Fereshteh Asgharzadeh · 1 shared paper, 2022 · strength 0.17
- Newsha Sardarzade · 1 shared paper, 2022 · strength 0.13
- Mohsen Aliakbarian · 1 shared paper, 2022 · strength 0.13
- Fatemeh Khojasteh‐Leylakoohi · 1 shared paper, 2022 · strength 0.13
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.